➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Harvard Business School
Mallinckrodt
Dow
McKesson

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FEBUXOSTAT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Febuxostat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00102440 ↗ Febuxostat Versus Allopurinol Control Trial in Subjects With Gout Completed Takeda Phase 3 2002-07-01 The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.
NCT00174915 ↗ Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. Completed Takeda Phase 3 2003-02-01 The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.
NCT00174941 ↗ Long-Term Safety of Febuxostat in Subjects With Gout. Completed Takeda Phase 2 2001-03-01 The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
NCT00174967 ↗ Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout Completed Takeda Phase 2 2001-01-01 The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout.
NCT00175019 ↗ Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed Takeda Phase 3 2003-07-01 The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
NCT00430248 ↗ Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed Takeda Phase 3 2007-02-01 The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
NCT00821392 ↗ Phase III Trial of Febuxostat in Korea Gout Patients Completed SK Chemicals Co.,Ltd. Phase 3 2006-08-01 This study was designed to evalute the efficacy and safety of Febuxostat after oral administration to patientd with gout in Korea
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Febuxostat

Condition Name

Condition Name for Febuxostat
Intervention Trials
Gout 31
Hyperuricemia 17
Chronic Kidney Disease 4
Hypertension 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Febuxostat
Intervention Trials
Gout 26
Hyperuricemia 24
Renal Insufficiency, Chronic 9
Kidney Diseases 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Febuxostat

Trials by Country

Trials by Country for Febuxostat
Location Trials
United States 387
Japan 30
Canada 18
Australia 11
Mexico 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Febuxostat
Location Trials
Texas 19
Florida 16
California 16
North Carolina 14
Georgia 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Febuxostat

Clinical Trial Phase

Clinical Trial Phase for Febuxostat
Clinical Trial Phase Trials
Phase 4 16
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Febuxostat
Clinical Trial Phase Trials
Completed 39
Not yet recruiting 19
Recruiting 10
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Febuxostat

Sponsor Name

Sponsor Name for Febuxostat
Sponsor Trials
Takeda 19
Ardea Biosciences, Inc. 6
AstraZeneca 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Febuxostat
Sponsor Trials
Industry 53
Other 48
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
McKinsey
Express Scripts
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.